Background-Variability in phenotypic characterization of coronary artery disease (CAD) may contribute to the heterogeneity of genetic association studies, and more consistency in phenotype definitions might improve replication of genetic associations. We assessed the extent of phenotypic heterogeneity and quantified its impact in a large literature sample of association studies. Methods and Results-We searched for large (Ն15 studies) meta-analyses of genetic associations and reviewed all studies included therein. From each primary study, we extracted phenotypic definitions, demographics, study design characteristics, and genotypic data. For each association, we assessed the magnitude and heterogeneity of genetic effects within and across CAD phenotypes, using meta-analytic methodologies. A total of 965 individual studies investigating 32 distinct variants in 22 genes were included, from which we grouped CAD phenotypes into 3 categories: acute coronary syndromes (ACS) (426 [44%] studies); angiographically documented disease (323 [34%] studies); and broad, not otherwise specified CAD (216 [22%] studies). These clinical phenotypes were overlapping. Subgroup meta-analyses by phenotype showed discordant results, but phenotypic classification generally explained small proportions of between-study heterogeneity. Differences between phenotypic groups were minimized for associations with robust statistical support. No CAD phenotype was consistently associated with larger or more homogeneous genetic effects in meta-analyses. Conclusions-Substantial phenotypic heterogeneity exists in CAD genetic associations, but differences in phenotype definition make a small contribution to between-study heterogeneity. We did not find a consistent effect in terms of the magnitude or homogeneity of summary effects for a specific phenotype to support its preferential use in genetic studies or meta-analyses for CAD. (Circ Cardiovasc Genet. 2011;4:58-67 .) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/cgi/content/full/CIRCGENETICS.110.957738/DC1.
G enetic association studies have improved our understanding of the underlying etiology of coronary artery disease (CAD), although key challenges remain in this research field. [1] [2] [3] Most gene-CAD associations proposed by candidate-gene studies have not been replicated by subsequent, well-powered studies. 4 Findings from agnostic genome-wide association studies (GWAS) have robust statistical support and a strong replication record; nevertheless, the identified variants confer small increments in risk and explain only a small proportion of the phenotypic variance of measured coronary atherosclerosis (stenotic lesions and extraluminal calcification) or occurrence of acute cardiac events. 5, 6 Several biological, methodological, and analytic factors have been proposed to explain both the failures of the candidate-gene approach and the missing heritability in GWAS. 1, 3, 6 Because CAD is a clinically heterogeneous entity, the issue of phenotypic heterogeneity may be of particular relevance to the study of CAD genetics.
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Problems with phenotypic characterization in CAD are well recognized. 3, 7 CAD can manifest with acute events, such as myocardial infarction (MI), or with chronic, stable symptoms of ischemia; thus, CAD case definitions can vary by using different clinical or imaging (angiographic) diagnostic criteria. Furthermore, identifying control subjects is difficult because CAD can exist during a prolonged asymptomatic phase and significant atherosclerosis can be missed by coronary angiography and stress testing. In response to the heterogeneous manner in which CAD can manifest, standardized phenotypic definitions (eg, MI and angiographic measures of disease burden) have been recommended for all genetic analyses. 2, 6 Although use of these "purer" phenotypes can be justified theoretically, there currently is no empirical evidence for improved sensitivity in detecting genetic effects compared with more heterogeneous CAD phenotypic definitions. Notably, use of more restrictive definitions is not without costs in terms of both the burdens of data collection and the compromised sample sizes.
The complexity of the CAD phenotype poses additional challenges for meta-analysis, which is a natural framework for evaluating replication of genetic associations and exploring reasons for inconsistencies among synthesized studies. 8 Genetic meta-analyses for CAD typically have included studies with varying phenotypic definitions, and statistical heterogeneity is commonly present. 9 However, to our knowledge, there has not been a systematic evaluation of the quantitative consequences of phenotypic heterogeneity, that is, whether between-study statistical heterogeneity can be attributed to phenotypic differences among synthesized studies and whether meta-analysis of studies with phenotypically homogeneous characteristics would result in stronger or more homogeneous effects.
We addressed these questions in a large-scale empirical evaluation of genetic association studies for the most extensively studied associations in CAD. Our study aims were to first describe the degree of heterogeneity of phenotypes in individual genetic association studies and then to investigate the impact of different phenotypic definitions on the magnitude and heterogeneity of genetic associations for CAD.
Methods

Study Sample and Data Extraction
All genetic association studies that had been included in large meta-analyses (quantitative syntheses of at least 15 primary studies) investigating the association between genetic variants and susceptibility to CAD were eligible for inclusion. The meta-analyses were identified by systematic searches in the Phenopedia database of the HuGE (Human Genome Epidemiology) Navigator 10 up to June 2009 (more details provided in online-only Data Supplement Tables 1 and  2) . We subsequently retrieved and reviewed all primary genetic association studies included in the eligible meta-analyses. From each publication, we extracted information on study design, population demographics, sampling strategy, phenotypic characteristics of cases and controls, genotypic distributions, and risk estimates for primary and secondary analyses. When necessary, we supplemented information from the corresponding meta-analysis publication. Data extraction was performed by 2 investigators (G.D.K. and I.J.D.), and all extracted data were cross-validated against the published information in the meta-analyses. Discrepancies were resolved through consensus.
Definition of Disease Phenotypes
We classified each study's phenotypic definition into 3 prespecified, mutually exclusive operational categories, which represent 3 distinct sampling strategies during subject enrollment:
1. Acute coronary syndromes (ACS phenotype), including MI (fatal and nonfatal) and unstable angina according to standard criteria (World Health Organization or universal definition criteria). 11 2. Angiographically documented disease (angiographic phenotype) defined as presence of stenosis above a certain threshold on a major epicardial artery on angiography. 3. Broadly defined CAD (broad phenotype) on the basis of varying clinical criteria and history of disease, or not otherwise specified, thus forming a catch-all category.
We also evaluated each study for additional case and control phenotypic characteristics and study design aspects 7,12-14 : a. Premature disease: study populations or subgroups that used cut-off inclusion criteria below age 55 years for men and 65 years for women. 15, 16 b. Age matching of controls to cases: used as a measure to avoid misclassification of subjects with latent, age-related disease. 7 c. Angiographic controls: angiographic documentation of absence of disease in controls; performed to avoid misclassification of subjects with developed but asymptomatic disease. 7 d. Retrospective or prospective design: if a genetic variant not only is associated with susceptibility to CAD, but also adversely influences survival, then the variant allele may be underrepresented in the survivors recruited in retrospective studies (case control or cross-sectional). Prospective studies (cohort or nested case control) would be less prone to such survival bias.
Statistical Analysis
We described the variability of phenotypes in individual genetic association studies by summarizing their characteristics overall as well as by phenotypic subgroup. We compared subgroups with parametric and nonparametric tests, as indicated. Further, we calculated the proportion of studies that satisfied the previously reported recommendations for phenotypic characterization of cases and controls. 7 We then used meta-analytic techniques to evaluate whether different phenotypic definitions of the disease can result in summary associations with differential magnitude and heterogeneity of genetic effects. The hypothesis tested here is that restrictive definitions (ie, ACS and angiographic) will have summary genetic effects of different magnitude (eg, larger odds ratios [ORs]) and smaller extent of statistical heterogeneity compared with the broad definition.
Data from all genetic association studies available for each genetic variant were resynthesized (all-inclusive meta-analyses), and the statistical significance (PϽ0.05) of the summary ORs was recorded. Our analyses focused on those associations with statistically significant summary ORs because these associations are presumably valid and can be examined for the impact of phenotypic definitions. We also separately examined the results from associations meeting more stringent criteria for statistical significance (PϽ0.01 for the summary OR). All associations are expressed as ORs with their corresponding 95% CIs. Summary ORs were estimated using the DerSimonian and Laird random effects model. 15 Between-study heterogeneity was tested with Cochran Q (considered statistically significant at PϽ0.10) and quantified with the I 2 statistic (an estimate of how much of the heterogeneity is unlikely to be due to chance). 15
Subgroup Meta-Analyses for Phenotypic Definitions
Each of the all-inclusive meta-analyses was stratified in 3 subgroup meta-analyses according to the phenotypic definition used by component studies (ACS, angiographic, or broad). Summary effect estimates and heterogeneity statistics were calculated for each subgroup.
Subgroup Comparisons of Magnitude of Effects
We examined whether the phenotypic subgroup-specific effects differed beyond what is expected by chance by calculating the relative OR (ROR) and its 95% CI for the summary effects between the subgroups. 16 The ROR expresses how much larger the summary genetic effect is in 1 phenotypic subgroup compared to another. For
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example, when comparing the genetic effects for ACS versus broad phenotypes, ROR Ͼ1 means that a genetic variant has a stronger genetic effect in studies where the disease is defined as ACS compared with studies in which broad phenotypes are used.
Subgroup Comparisons of Heterogeneity
I 2 values obtained from each subgroup were compared with the Mann-Whitney U test. We also examined how much of the observed statistical heterogeneity could be explained by consid- ering the phenotypic subgroups. This analysis was done with the Q statistic partitioning technique as follows: The overall heterogeneity of the all-inclusive meta-analysis (Q ALL ) was partitioned into that which could be explained by differences between subgroups (Q phen ) and that which remained unexplained within the subgroups (Q broad , Q angiographic , Q ACS ). Then, the heterogeneity explained by the differences between the subgroups was calculated as Q phen ϭQ ALL Ϫ(Q broad ϩQ angiographic ϩQ ACS ) and was compared with critical values of the 2 distribution with 2 degrees of freedom. 17
Secondary Analyses
The additional study characteristics of interest were examined for their potential impact on genetic effects in additional subgroup analyses. Complementary to all aforementioned subgroup analyses, we performed meta-regression analyses that provided similar results (shown in online-only Data Supplement). Finally, we conducted exploratory statistical power calculations for the comparisons of magnitude of effects under a range of representative scenarios. 18 For all comparisons, except those for heterogeneity, statistical significance was defined as PϽ0.05. All tests were 2 sided. Statistical analyses were performed with Stata (StataCorp; College Station, TX), SAS (SAS Institute Inc; Cary, NC), and Meta-Analyst (Tufts Medical Center; Boston, MA) software. 19 
Results
Synopsis of Primary Study Characteristics
The HuGE Navigator search identified 71 titles that met the search criteria ( Figure 1 ). Of those, 19 articles (online-only Data Supplement Table 1 ) describing 32 meta-analyses for 22 distinct genes were considered eligible for analysis, resulting in 965 genetic association studies (meta-analytic strata) that were finally included in our analyses (Figure 1 and onlineonly Data Supplement Table 2 ). Summary characteristics of these genetic association studies are presented in Table 1 . Most (93%) studies were retrospective in design, had small samples, and examined populations that consisted mainly of non-Hispanic whites and male participants. When comparing summary study characteristics against the previously reported recommendations for phenotypic characterizations, 7 we found that the majority of studies in the field did not follow most of the recommendations ( Table 2) .
On the basis of the case sampling strategy used in the primary analysis of each study, the 965 genetic association studies were classified into 3 phenotypic subgroups: 426 (44%) studies were classified into the ACS subgroup, 323 (33%) into the angiographic subgroup, and 216 (22%) into the broad subgroup. The ACS subgroup comprised almost exclusively MI populations because Ͻ10% of these studies included patients with unstable angina and no history of MI. The angiographic subgroup included cases in which a coronary stenosis was detected on conventional angiography in at least 1 epicardial vessel. The 50% stenosis cut-off was used 
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by the majority of studies, with only 43 (13%) limiting enrollment to patients with more severe stenosis (Ն70%). Angiographic verification of control status was performed in 32% of the angiographic subgroup studies. The broad sub-group included variable combinations of patient populations with a history of MI, revascularization (angioplasty or bypass surgery), positive exercise test findings or baseline ischemic electrocardiographic findings, symptomatic angina, fatal CAD with autopsy findings, or history of hospitalization for CAD-related diagnoses. Genotypic information for the components of the broad definition was commonly unavailable. Study design characteristics and demographics of participants were found to be significantly different across the 3 phenotypic subgroups (Table 1) . Although these phenotypic subgroups comprised different study samples and, thus, did not overlap, more than half of the patients included in studies with angiographic and broad definitions suffered from ACS as well ( Figure 2 , Table 1 ). In 120 studies with angiographic or broad definitions, detailed genotypic information was available for patient subgroups stratified by history of ACS. We found that the genotypic distribution between these clinically nonoverlapping patient subgroups was significantly different ( 2 PϽ0.05) in a small number of studies (nϭ19; 16%).
Analysis of Phenotypic Effects With Meta-Analytic Techniques
All-Inclusive Meta-Analyses
We resynthesized results from all eligible genetic association studies with a random-effects model and found statistically significant effects in 19 meta-analyses, whereas no significant signal was found in the remaining 13 meta-analyses (onlineonly Data Supplement Tables 3 to 6 ). The 19 associations with statistically significant summary ORs involved 15 genes: 5 (APOB, LPL, PON1, CETP, APOE) belong to the lipid metabolism pathway; 4 are involved in thrombotichemostatic functions (SERPINE1, F13A1, F5, F2); 4 relate to endothelial dysfunction (NOS3, ESR1, MTHFR, ACE); 1 relates to inflammation (CD14); and 1 genetic variant (9p21 locus) has unknown functions. 1, 20 
Subgroup Meta-Analyses
Results from subgroup analyses are shown in Figure 3 and online-only Data Supplement Table 3 . Statistically significant ORs are present across phenotypic subgroups, with only 2 (11%) of the 19 associations (9p21-rs1333049 and ACE-rs4340) being significant in all examined subgroups. The 
(12) §
No family history of CAD 69 (7) No history of cerebrovascular or peripheral artery disease
(81)ʈ
Age much greater than cases by 10-20 years 0 (0) ¶ Data are presented as no. (%). *Studies that used the broad or angiographic definitions. †The definitions of low-risk subgroups (eg, lack of diabetes or normal lipid levels) were varying across these studies.
‡Angiographic evaluation was not used as an inclusion criterion in ACS studies.
§All 118 studies used coronary angiography. (Multidetector CT was not used by any study.)
ʈOne hundred eighteen (19%) studies included patients free from overt cardiovascular disease but with cardiovascular risk factors (eg, diabetes, hypertension, obesity, dialysis) or undergoing selective coronary angiography for evaluation of atypical chest pain or other indications. ¶In 30 (3%) studies, the mean age of control subjects exceeded the mean age of cases by 5 years. No studies with a 10-year difference were identified.
angiographic subgroup had the highest proportion of significant ORs (10/19; 53%); all significant ORs in this subgroup were observed for lipid metabolism and endothelial dysfunction genes. For the ACS subgroup, significant ORs were found in 8 (42%) associations. The ACS phenotype has significant ORS in 3 of the 4 associations in the thrombotichemostatic pathway genes. The broad phenotype had fewer statistically significant results (31%), but this could result from diminished statistical power because smaller numbers of component studies investigated this phenotype.
Subgroup Comparisons of Magnitude of Effects
We observed statistically significant RORs in 10 (18%) of the 57 comparisons performed (online-only Data Supplement Table 4 ), which corresponded to 5 associations (LPL-rs320, F13A1-rs5985, NOS3-rs2070744, ESR1-rs2234693, and CD14-rs2569190). In 3 of these associations (LPL-rs320, F13A1-rs5985, NOS3-rs2070744), the significant RORs were accounted for by a different directionality of the OR in the broad subgroup compared to the other subgroups ( Figure 4) . The expected genetic effects difference of the restrictive phenotypes (ACS or angiographic) versus the broad phenotype was not supported by our results; almost half of the significant RORs for these comparisons were Ͻ1. Apart from LPL-rs320, none of the other lipid metabolism genes had a significant ROR when the angiographic phenotype was compared to the broad phenotype.
Subgroup Comparisons of Heterogeneity
Pair-wise comparisons of the I 2 statistics obtained from the 3 subgroup analyses were not statistically significant (all Mann-Whitney PϾ0.05), showing that no phenotypic subgroup was found to have a consistently smaller extent of statistical heterogeneity. The Q test partitioning analysis for the 3 phenotypic subgroups showed statistically significant between-subgroup heterogeneity in 9 (47%) of the 19 metaanalyses; however, this between-subgroup heterogeneity explained small proportions of the overall between-study variance ( Figure 5 , online-only Data Supplement Table 4 ).
In the sensitivity analysis of 12 associations meeting more stringent criteria of statistical significance (PϽ0.01) (onlineonly Data Supplement Table 7 ), we found that phenotypespecific effects were less common. Significant RORs were found only for NOS3-rs2070744 and the Q partitioning analysis was statistically significant in 5 (42%) associations.
Secondary Analyses
Detailed results from secondary analyses are presented in online-only Data Supplement tables 7 to 15. None of the examined variables was found to be a strong driver of statistical heterogeneity across all examined associations. The presumed superiority of premature disease to detect stronger genetic effects was confirmed for only for 2 of the 11 examined associations (MTHFR-rs1801133 and 9p21-rs1333049) (online-only Data Supplement Table 10 ). Most of the analyses for control group characteristics were nonsignificant (online-only Data Supplement Tables 12 and 13 ). The analysis of study designs showed, with the exception of 9p21-rs1333049, that synthesis of prospective studies resulted in nonsignificant summary ORs. The comparisons of effect sizes between prospective and retrospective studies 
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were consistent with a weaker genetic effect in the prospective ones (online-only Data Supplement Table 14 ). Statistical power was generally limited for the detection of small RORs (online-only Data Supplement Table 15 ).
Discussion
Novel Findings
Our systematic evaluation of phenotypic heterogeneity in the field of CAD identified extensive variability in the way that the disease is defined at the individual study level. We observed a broad spectrum of inclusion criteria in terms of type of disease (acute or stable, recent onset or chronically present, fatal or not), severity of disease (eg, various thresholds of angiographic stenosis), age at onset (from the second to the eighth decade of life), health status of controls (ranging from neonates and healthy blood donors to patients with cardiovascular risk factors undergoing invasive angiography), and other design aspects.
Our work provides a large-scale empirical evaluation of the consequences of this phenotypic heterogeneity. We found evidence that the phenotypic sampling strategy used by individual studies accounts for a small proportion of the observed statistical heterogeneity in certain meta-analyses. The effect size estimates of subgroup analyses according to phenotype often were discordant between subgroups in terms of direction of effects and statistical significance. However, we failed to identify a specific sampling strategy that has consistently larger genetic effects or produces less heterogeneous results. We examined additional study-level characteristics (premature disease, control definitions, prospective design), but none of these factors was found to be a strong driver of statistical heterogeneity; nevertheless, we found evidence that prospective studies are associated with attenuated genetic effects for certain associations.
Limitations of Clinical Phenotypes
Although CAD is common with advanced age, only a fraction of vulnerable patients will ever develop an acute event. 21, 22 Dissecting the phenotype of MI/ACS from underlying CAD has been recommended on the basis of clinical differences between the 2 entities, pathophysiological dissimilarities, and higher heritability estimates for the MI phenotype. 7, 21, 23 Phenotypic homogeneity of MI is elusive because of the diverse manner of presentation, such as ST-elevation and non-ST-segment elevation MIs that may be attributed to distinct pathophysiological mechanisms, 24 and survival bias. 7 On the other hand, the angiographic criteria for CAD 7 are problematic because the coronary angiography cannot quantify the accumulation of atherosclerosis within arterial walls. 25 We found considerable conceptual overlap among the populations from 3 different sampling strategies (Figure 2) , which may be explained by the natural history of atherosclerosis across the continuum from fatty streaks to vulnerable plaques or fixed blockages. 22 Early stages of atherosclerosis (ie, lipid oxidation, macrophage infiltration, or platelet reactivity) may be more directly influenced by genetic determinants. Such quantitative intermediate phenotypes for CAD (eg, cholesterol levels, blood pressure, coronary calcium quantity) could serve as proximate and more sensitive physiological markers of genetic effects. 26, 27 Pathophysiologically distinct clinical definitions of CAD (eg, acute versus chronic) also may be useful for identifying the genomic culprits of different disease processes (eg, CAD onset and progression or ACS precipitation). 28, 29 Despite the theoretical advantage of such possible definitions, we identified a paucity of relevant analyzable data in the available literature.
Implications for Future Research
Regarding the design of future meta-analyses, we demonstrated that the totality of evidence for CAD phenotypes should be considered. Subgroup phenotypic analyses have reduced statistical power, the majority of phenotype-specific genetic effects do not typically differ beyond chance, and patient groups show extensive overlap. Phenotypic subgrouping may be informative as an exploratory secondary analysis because phenotype-specific effects, when present, are unpredictable.
Most of the associations analyzed herein have emerged from candidate-gene studies, a body of evidence with well-recognized limitations. 3 Nevertheless, the recommendations to favor particular CAD definitions in discovery data sets or replication studies are not supported by the available evidence. This is further reinforced by the fact that we did not find evidence of phenotype-specific effects for the 2 variants (9p21-rs1333049 and ACE-rs4340) with the strongest statistical support (PϽ10 Ϫ8 ). The 9p21 locus variant that was discovered by GWAS did show stronger effects for premature disease (ROR, 1.13; 95% CI, 1.05 to 1.21), in agreement with a recent analysis. 30 When conducted on such definitive association findings, phenotypic heterogeneity analyses are expected to be very informative and will be worth pursuing once adequate evidence from GWAS accumulates. 
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Study Limitations
This project analyzed study-level rather than individual patient-level data. Although significant findings can generate hypotheses to be tested in well-designed primary studies, we cannot rule out competing explanations for significant findings by our study design. Selective reporting can hamper our analyses if investigators perform analyses by using different phenotypic definitions of outcomes and report only the most significant results. 31 Additionally, differential publication bias by phenotype definition may exist if reviewers or journal editors have a positive predisposition to studies with clear phenotypes and significant results. Because the prevalence of such practices is unknown, all published evidence was taken at face value. We have examined a large number of studylevel variables across many genetic associations, and thus, some positive findings may be due to chance. The racial diversity of included populations also may have influenced the examined genetic associations, particularly when the investigated variant is tagging the causal one in a racespecific haplotypic structure. However, the biological impact of common variants has been shown to be usually consistent across racial groups, and the populations analyzed were mostly white. 32 The lack of statistically significant findings for the majority of the phenotypic and the secondary subgroup comparisons may be due to a lack of statistical power for certain comparisons, as illustrated by our exploratory power analyses and the relatively broad CIs for many RORs. The identified limited contribution of phenotypes to explain between-study heterogeneity does not necessarily mean that there are no true differences in the influences of genetic variants at the level of the regulated pathophysiology. Such differences may exist, but we were not able to detect them because of overlaps in clinical definitions, small numbers of studies per metaanalytic stratum, and lack of patient-level data. Nevertheless, by compiling the largest compendium of studies for CAD to date, we were able to detect significant results for certain genetic associations, and we highlighted the limitations of the available literature.
Conclusions
Our analysis identified extensive phenotypic heterogeneity among cohorts of patients with CAD studied to date, which may contribute to the heterogeneity of genetic association study results. However, we did not find a consistent effect in terms of the magnitude or homogeneity of summary effects for a specific phenotype to support its preferential use as a phenotype for primary analyses. Phenotype testing can be informative as a secondary analysis after an association with the disease has been established. 28 This project provides an analytic framework for testing phenotypespecific effects in meta-analysis. Further empirical evidence on emerging replicated GWAS findings and additional analyses on primary association data in well-characterized cohorts have the potential to highlight critical information for the impact of phenotypes.
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